Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Stockholders' Equity

v3.3.1.900
Consolidated Statement of Stockholders' Equity - USD ($)
Series B Preferred Stock [Member]
Non-Designated [Member]
Series C Preferred Stock [Member]
Series D Preferred Stock [Member]
Series E Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive Income / Loss [Member]
Deferred Issuance Costs [Member]
Noncontrolling Interest [Member]
Retained Earnings [Member]
Total
Beginning balance, shares at Dec. 31, 2013 5,000 0   0 0 5,000 12,274,386            
Beginning balance, value at Dec. 31, 2013 $ 1 $ 0   $ 0 $ 0 $ 1 $ 122,744 $ 1,785,479 $ 0 $ (12,500) $ 121,004 $ 6,752,485 $ 8,769,213
Common stock issued for services, shares             29,494            
Common stock issued for services, value             $ 295 179,705         180,000
Common stock issued for accrued bonuses, shares             86,024            
Common stock issued for accrued bonuses, value             $ 860 524,140         525,000
Common stock issued for acquisition of assets, shares             4,096            
Common stock issued for acquisition of assets, value             $ 41 24,959         25,000
Preferred stock issued in acquisition, shares       200,000 100,000 300,000              
Preferred stock issued in acquisition, value       $ 20 $ 10 $ 30   2,049,970         2,050,000
Stock option expense               672,079         672,079
Common stock returned from shareholder and cancelled, shares             (508,586)            
Common stock returned from shareholder and cancelled, value             $ (5,086) 5,086          
Write-off of deferred issuance costs                   12,500     12,500
Dividends on Series B preferred stock                       (5,010,300) (5,010,300)
Net income                       7,820,332 7,820,332
Ending balance, shares at Dec. 31, 2014 5,000 0   200,000 100,000 305,000 11,885,414            
Ending balance, value at Dec. 31, 2014 $ 1 $ 0   $ 20 $ 10 $ 31 $ 118,854 5,241,418 0 0 121,004 9,562,517 15,043,824
Common stock issued for services, shares             317,469            
Common stock issued for services, value             $ 3,175 2,901,825         2,905,000
Stock options exercised for common stock, shares             409,638            
Stock options exercised for common stock, value             $ 4,096 2,495,904         2,500,000
Preferred stock converted to common stock, shares converted       (200,000) (55,000) (255,000)              
Preferred stock converted to common stock, shares issued       (20) (6) (26)              
Preferred stock converted to common stock, value converted             887 (861)          
Preferred stock converted to common stock, value issued             $ 88,751            
Stock option expense               722,829         722,829
Allocation of offering proceeds to derivative liabilities               (7,019,355)         (7,019,355)
Adjust minority interest in Biohealth                     (121,004)   (121,004)
Ending balance, shares at Nov. 02, 2015 5,000 0 0 0 45,000 50,000 12,701,272            
Ending balance, value at Nov. 02, 2015 $ 1 $ 0 $ 0 $ 0 $ 4 $ 5 $ 127,012 11,361,115 0 0 0 9,562,517 21,050,649
Beginning balance, shares at Dec. 31, 2014 5,000 0   200,000 100,000 305,000 11,885,414            
Beginning balance, value at Dec. 31, 2014 $ 1 $ 0   $ 20 $ 10 $ 31 $ 118,854 5,241,418 0 0 121,004 9,562,517 15,043,824
Write-off of deferred issuance costs                         0
Dividends on Series B preferred stock                         (1,627,188)
Net income                         (34,730,539)
Ending balance, shares at Dec. 31, 2015 5,000 0 9,000 0 45,000 59,000 14,395,171            
Ending balance, value at Dec. 31, 2015 $ 50 $ 0 $ 90 $ 0 $ 450 $ 590 $ 143,951 25,456,870 0 0 0 (26,795,210) (1,193,799)
Beginning balance, shares at Nov. 02, 2015 5,000 0 0 0 45,000 50,000 12,701,272            
Beginning balance, value at Nov. 02, 2015 $ 1 $ 0 $ 0 $ 0 $ 4 $ 5 $ 127,012 11,361,115 0 0 0 9,562,517 21,050,649
Cancellation of Medytox shares, shares cancelled (5,000)       (45,000) (50,000)              
Cancellation of Medytox shares, value $ (1)       $ (4) $ (5)   5          
Issuance of Rennova shares, shares issued 5,000       45,000 50,000              
Issuance of Rennova shares, value $ 50       $ 450 $ 500   (500)          
Common stock issued for cash, shares     9,000     9,000 645,161            
Common stock issued for cash, value     $ 90     $ 90 $ 6,452 8,836,795         8,843,337
Shares issued in merger with CollabRx, Inc.. shares             1,048,738            
Shares issued in merger with CollabRx, Inc.. value             $ 10,487 12,278,810         12,289,297
Dividends on Series B preferred stock                       (1,627,188) (1,627,188)
Net income                       (34,730,539) (34,730,539)
Ending balance, shares at Dec. 31, 2015 5,000 0 9,000 0 45,000 59,000 14,395,171            
Ending balance, value at Dec. 31, 2015 $ 50 $ 0 $ 90 $ 0 $ 450 $ 590 $ 143,951 $ 25,456,870 $ 0 $ 0 $ 0 $ (26,795,210) $ (1,193,799)